---
title: "INCR.US (INCR.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INCR.US/news.md"
symbol: "INCR.US"
name: "INCR.US"
parent: "https://longbridge.com/en/quote/INCR.US.md"
datetime: "2026-05-20T14:46:52.947Z"
locales:
  - [en](https://longbridge.com/en/quote/INCR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INCR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INCR.US/news.md)
---

# INCR.US (INCR.US) — Related News

### [InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News](https://longbridge.com/en/news/284844092.md)
*2026-04-30T14:05:42.000Z*
> InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News

### [Extendicare Sets Date for Q1 2026 Results and Investor Call](https://longbridge.com/en/news/281766836.md)
*2026-04-06T13:43:52.000Z*
> Extendicare Sets Date for Q1 2026 Results and Investor Call

### [Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care](https://longbridge.com/en/news/279298091.md)
*2026-03-16T16:34:39.000Z*
> Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

### [Cervical cancer prevention and treatment, a historic night](https://longbridge.com/en/news/277720210.md)
*2026-03-04T03:49:12.000Z*
> APL-1702 has officially been approved, becoming the world's first non-surgical, non-invasive treatment product for CIN2 

### [InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement | INCR Stock News](https://longbridge.com/en/news/277682283.md)
*2026-03-03T13:46:00.000Z*
> InterCure Ltd. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its sh

### [InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans](https://longbridge.com/en/news/276335790.md)
*2026-02-19T13:01:20.000Z*
> InterCure reported preliminary 2025 results with estimated revenue of NIS 265 million, an 11% year-on-year increase, and

### [Why Investors Shouldn't Be Surprised By InterCure Ltd.'s (TLV:INCR) 29% Share Price Plunge](https://longbridge.com/en/news/272497690.md)
*2026-01-14T04:20:43.000Z*
> InterCure Ltd. (TLV:INCR) has seen its share price drop 29% in the last month and 49% over the past year, raising concer